Confronto
Cagrilintide vs. Liraglutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
1415456-99-3
204656-20-2
Peso molecolare
4253.7 g/mol
3751 g/mol
Emivita
168 h
13 h
Sequenza
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYHAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGMeccanismo d'azione
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
5
di cui sull'uomo
3
4
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Cagrilintide and Liraglutide?
- Cagrilintide is classified as "Metabolico", while Liraglutide is classified as "Metabolico". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Liraglutide?
- The highest available evidence level is "RCT sull'uomo" for Cagrilintide and "RCT sull'uomo" for Liraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Liraglutide in Germany and the United States?
- Germania: Cagrilintide — Non approvato, Liraglutide — Su prescrizione. Stati Uniti: Cagrilintide — Non approvato, Liraglutide — Su prescrizione. These are factual summaries with source and review date on the individual pages.